Abstract:Abstract The rise of Targeted Protein Degradation (TPD) is rapidly changing perceptions about therapeutic target druggability and is rewriting many preconceived notions on drug design. However, the majority of monovalent molecular glue and heterobifunctional degraders in clinical and preclinical development rely predominantly on the recruitment of a single E3 ligase, Cereblon. Arising resistance, toxicities and restricted Protein-of-Interest scope may limit clinical potential, highlighting the need to uncover novel TPD mechanisms. To expand the potential of this modality, we have developed SITESEEKER®, a screening technology operating at substantially greater magnitude of complexity than extant target discovery platforms. SITESEEKER® utilizes computationally-derived encoded mini-protein fragments with huge shape diversity to systematically identify novel degrader mechanisms and define functionally-active binding sites on targets. SITSEEKER® allows for the discovery of targets that may be missed through traditional gene editing or knockdown approaches and can additionally provide valuable mechanistic insights that help to inform, unlock and truncate the path from target ID to drug discovery. We describe the identification of a cache of degrader motifs which showcase the breadth of proteome space yet to be explored within TPD. Moreover, we identify peptide motifs capable of driving degradation in a selective manner with potential to be translated into tissue- or cancer-selective degraders. The functional dependencies of prioritized degraders have been mapped to their cognate E3 ligase using combinatorial screening, giving rise to a number of E3 ligases with potential to be hijacked for TPD. PhoreMost is progressing a pipeline of monovalent and heterobifunctional oncology degrader programs arising from its platform. We demonstrate the effective hijacking of selected E3 ligases, identified by SITESEEKER®, through the discovery of high affinity small molecule binders and subsequent discovery of efficient heterobifunctional degraders against selected Proteins-of-Interest. Citation Format: Christian Dillon. Systematic identification of novel targeted protein degradation mechanisms using SITESEEKER® technology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6052.

Proximity-dependent protein (de)stabilization: screening the human ORFeome for protein degraders and stabilizers

Proteome-scale discovery of protein degradation and stabilization effectors

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

The targeted protein degradation landscape

High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics

Bivalent Ligands for Protein Degradation in Drug Discovery

Abstract 6052: Systematic identification of novel targeted protein degradation mechanisms using SITESEEKER® technology

Advancing targeted protein degradation for cancer therapy

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

Characterisation of high throughput screening outputs for small molecule degrader discovery

Targeted protein degradation: from mechanisms to clinic

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Targeted protein degradation via intramolecular bivalent glues

Investigating Protein Degradability through Site-Specific Ubiquitin Ligase Recruitment

Confounding factors in targeted degradation of short-lived proteins

Targeted protein degradation in drug development: Recent advances and future challenges

Protein degrons and degradation: Exploring substrate recognition and pathway selection in plants

Targeted degradation of Pin1 by protein-destabilizing compounds

Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy